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Abstract 
Background 
In patients with brain tumors the choice of the antiepileptic medication is guided by 
tolerability and pharmacokinetic interactions. This study investigated the effectiveness of 
levetiracetam (LEV) and pregabalin (PGB), two non enzyme-inducing agents, in this setting. 
 
Methods 
In this pragmatic, randomized, unblinded phase II trial (NCT00629889), patients with 
primary brain tumors and epilepsy were titrated to a monotherapy of LEV or PGB. Efficacy 
and tolerability were assessed using structured questionnaires. The primary composite 
endpoint was the need to discontinue the study drug, add-on of a further antiepileptic 
treatment, or occurrence of at least 2 seizures with impaired consciousness during one year 
follow-up. 
 
Results 
Over 40 months, 25 patients were randomized to LEV, and 27 to PGB. Most were middle-
aged men, with a high grade tumor, and at least one generalized convulsion. Mean daily 
doses were 1125mg (LEV) and 294mg (PGB). Retention rates were 59% in the LEV, and 
41% in the PGB group. The composite endpoint was reached in 9 LEV and 12 PGB patients: 
need to discontinuation (side effects: 6 LEV, 3 PGB; lack of efficacy: 1 and 2; impaired oral 
administration: 0 and 2), add-on of another agent (1 LEV, 4 PGB), and 2 seizures impairing 
consciousness (1 in both). Seven LEV and 5 PGB subjects died of tumor progression.  
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Conclusions 
This study shows that LEV and PGB represent valuable monotherapy options in this setting, 
with very good antiepileptic efficacy and an acceptable tolerability profile, and provides 
important data for the design of a phase III trial. 
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Introduction 
Seizures in patients with primary brain tumors represent a frequent problem, as at least one 
third of patients develop epilepsy in the course of disease 1,2. Subjects experiencing a first 
seizure should benefit from antiepileptic drug prescription (AED) aiming at reducing further 
generalized convulsive events and improving quality of life 3. There is a wide consensus 
favoring the use non enzyme-inducing AED to avoid hepatic interactions potentially 
interfering with chemotherapy and other medications, such as steroids 4-8, but the level of 
evidence is still very limited, as recently pointed out 9. Furthermore, although all the newer 
AEDs were initially registered as add-on drugs in combination, recent experience suggest 
efficacy as single agents.  
 
Among the newer AED, levetiracetam (LEV) and pregabalin (PGB) are considered among 
the most favorable compounds in terms of potential pharmacokinetic drug-drug interactions. 
LEV binds to a synaptic vesicle protein 10, lacks hepatic catabolism (it is excreted partly 
unchanged in the urine and partly undergoes extrahepatic hydrolysis) 11, and is available in 
oral and intravenous formulations. It can be quickly titrated, displaying therapeutic efficacy 
within hours 12, and its bioavailability in the cerebrospinal fluid (CSF) seems longer than the 
plasmatic half-life 13. PGB modulates Q-type voltage-sensitive calcium channels 14, does not 
undergo any metabolic transformation (it has a complete renal excretion), and therefore does 
not have any impact on the hepatic cytochromic system 15,16. Despite being limited to oral 
formulations, it may also be titrated rapidly, exerting therapeutic efficacy within 48 hrs 17, 
and as opposed to gabapentin, which has an identical mechanism of action, PGB does not 
depend on a saturable intestinal resorption 18. 
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This study was conducted to determine the safety and efficacy of AED monotherapy with 
LEV or PGB in patients with primary brain tumors and epilepsy, and to collect prospective 
data on seizure control in brain tumor patients.  
 
 
Methods 
Design and patients 
This was a pragmatic randomized open label phase II randomized trial conducted in 2 Swiss 
brain tumor centers. Subject were included if aged > 18 years, having a primary brain tumor 
(WHO grade II-IV) provoking a least one previous seizure, therefore justifying introduction 
of AED treatment 19, and with a potential need of chemotherapy. All patients provided 
written informed consent. Exclusion criteria were status epilepticus on enrolment (defined as 
prolonged seizures >5 minutes needing emergent treatment 20), need of intravenous AED, 
requirement of a concomitant medication with another AED, a modified Rankin scale ≥4, 
known intolerance to the study drugs, pre-existent psychosis, current suicidality, a life 
expectancy shorter than 4 weeks, or a current pregnancy (urine test was required on 
enrolment for women < 50 years of age) Patients receiving other AEDs at the time of 
enrolment were eligible especially if they were inducing AED and if these could be 
discontinued within 2 weeks of enrolment; patients on phenobarbital were not included. 
 
The study was approved by the ethic committees of the two participating Swiss university 
hospitals (Centre Hospitalier Universitaire Vaudois, University Hospital Zurich), and 
registered under Clinicaltrials.gov NCT00629889. Patients were randomized using a 
computerized predefined randomly drawn allocation series, treatment was to be started at 
randomization.  
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Treatments 
AEDs consisted of either LEV or PGB at increasing doses up to 2 x1500 mg of LEV, or 2 x 
300 mg of PGB. The starting doses were: LEV 2x250mg or PGB 2x75, with increments 
(500mg LEV; 150mg/PGB) in intervals of at least 24hrs. Dose adaptation occurred at the 
discretion of the treating neurologist in accordance with standard practice, if needed a 
transient prescription (<3 days) of benzodiazepine, but of no other AED, was allowed.  
 
Follow-up and procedures 
The observation time within the trial was determined at 1 year. Fixed follow-up visits were 
scheduled at week 2; and after 2, 6 and 12 months of therapy. Baseline assessments included 
a full medical and neurological examination, ECG, EEG, brain MRI, a laboratory work up 
(including hematology, electrolytes, liver transaminases, creatinine), and seizures types and 
frequency. Potential adverse events were assessed using the NCI CTCAE version 3 21, at 
baseline and during follow-up through a structured interview. The latter included the 
following items: fatigue, somnolence (Epworth sleepiness scale), headache, dizziness, blurred 
vision, irritability, anxiety, psychosis, concentration problems, infections requiring 
antibiotics, skin rash, peripheral edema, subjective disturbance of cardiac rhythm, erectile 
dysfunction, and lowering of libido. Furthermore, during each visit patients were asked about 
current medication (compliance was categorized after subjective reports as optimal versus 
suboptimal if more than 1 dose/week was omitted), seizures type and frequency; they 
received a neurological examination, were weighted and arterial blood pressure and pulse 
were measured, and the modified Rankin scale was assessed. A laboratory work-up was 
repeated on each visit (except two weeks after enrollment). 
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Endpoints, sample size and statistics: 
The primary endpoint was the survival free of the composite of the following endpoints, 
reflecting pragmatically the failure of an AED monotherapy: status epilepticus, 2 seizures 
with impaired consciousness, need of a second AED, need to discontinue the study drug (lack 
of efficacy or adverse reactions). Secondary endpoints were occurrence of any adverse event, 
occurrence of any component of the endpoint, and mortality. For adverse events, we 
considered any progression on the 21 grading for any item during follow-up; worsening of the 
Epworth sleepiness scale was categorized if an increase of 5 points was reported.  
 
It was assumed that at the end of the one-year follow-up about 25% of patients would have 
experienced status epilepticus or 2 seizures with consciousness impairment, 15% intolerable 
side effects, and 25% would need add-on treatment 3,22,23. Taking overlaps into account, the 
composite endpoint would have been reached by about 50% of study subjects. Targeting at 
least 10 subjects reaching the composite endpoint in each arm, and assuming that these would 
correspond to the lower limit of the 95% CI using a binomial distribution, 30 patients would 
have been required in each arm. 
 
Analysis was performed as intention to treat for patients receiving at least one study drug 
dose. The variables of interest were assessed using descriptive statistics (mean ±SD; median, 
range; or simple proportions, as needed), and Kaplan-Meier survival curves; patients who 
died because of tumor progression or that were lost to follow-up were censored. As the study 
was designed as a Phase II trial, no comparison was undertaken between the two study drugs. 
Calculations were performed on a Stata software, version 12 (College Station, TX). 
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Results 
Between March 2008 and July 2011, 52 patients were enrolled in the two participating 
centers. Recruitment was stopped after reaching the composite endpoint in 21 subjects. 
Patient characteristics are depicted in Table 1. Most were middle-aged men, with a high 
grade glioma, having presented with at least one generalized convulsion, having an abnormal 
neurological examination and EEG, and being very slightly clinically impaired. Slightly more 
than half of patients were on another AED (14 (56%) in the LEV arm, 13 (48%) in the PGB 
arm) before study entry: 10 on phenytoin, 6 on carbamazepine, 5 each on valproate or 
benzodiazepines, one on lamotrigine. All patients had gliomas. Table 2 shows data regarding 
study medication and clinical evolution during the study. After two weeks, many patients 
were already on target drug dosage, which was further increased in the minority of them over 
the study; most reported a good compliance with the study medication; about 1/3 experienced 
tumor progression.  
 
After 1 year of follow-up, over one third of the patients failed therapy as defined per study 
endpoint: 9 in the PGB and 12 in the LEV treated group. Two subjects who did not return for 
scheduled follow-up visits (1 early death due to tumor progression, 1 lost to follow-up) were 
censored. Table 3 summarizes the study endpoints. The composite endpoint was reached by 
more than one third of subjects: while no episode of status epilepticus and only 2 patients 
with occurrence of 2 seizures with impaired consciousness were recorded, in most cases the 
study drug was discontinued. This occurred in 7 patients in the LEV group (6 because of side 
effects: irritability, psychosis, dizziness, fatigue, headache, thrombopenia; 1 due to lack of 
efficacy), and 7 in the PGB group (3 for side effects: depression, sexual dysfunction, nausea; 
2 because of impossibility to administer PGB orally due to tumor progression and worsening 
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of clinical conditions; 2 because of lack of efficacy). Globally, 65% of patients on LEV and 
75% on PGB remained seizure free until last follow up. 
 
About one quarter of patients died during the study; no death was considered study drug-
related. One patient taking LEV had a severe reduction in platelet counts that lead to study 
discontinuation; this represented the only severe adverse event (and chemotherapy may have 
played the predominant role). The median retention of the allocated study drug was about 9.5 
months in the LEV group and 5.5 months in the PGB group. Figure 1 illustrates the Kaplan-
Meier curves for both medications. Nine patients (36%) in the LEV group and 7 (26%) in the 
PGB were still taking their study medication after one year; considering censored patients, 
this corresponds to 59% in the LEV and 41% in the PGB group. Table 4 shows details 
regarding adverse events. The items most frequently associated with LEV administration 
were somnolence, depression, and concentration problems; in the PGB group, these were 
related to dizziness, concentration problems, and depression. Conversely, erectile 
dysfunction, psychosis, skin rash, and weight increase were reported very rarely in both 
groups. Overall, there were major hematological disturbances, probably related to 
concomitant chemotherapy. 
 
 
Discussion 
In this randomized phase II study, half of the enrolled patients remained on the allocated 
AED at 1 year; the primary reason of AED discontinuation was not lack of seizure control, 
but side effects. To the best of pour knowledge, this is the first RCT addressing seizure 
control of two non-enzyme-inducing agents used as monotherapy in brain tumor patients over 
one year.  
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Only two prospective studies assessing LEV monotherapy in similar settings have been 
conducted 22,24. Others tested LEV for 4 weeks in selected populations undergoing tumor 
resections 25,26; the only randomized assessment is related to one trial focused on patients 
after craniotomy switched to LEV from phenytoin in a 2:1 ratio and followed for 6 months 27. 
Apart from our previous retrospective pilot analysis 23, no monotherapy study has been 
performed on PGB.  
 
Reflecting its pragmatic approach, our study population is similar to other studies on the 
same topic in terms of demographics (mean age 53 yo, 60% men), brain tumor severity (71% 
high grade), and seizure type (generalizations in 56%) 3,22-24. Twenty-three percent of patients 
died following brain tumor progression during the study; this is roughly similar to 34% 22, 
while no patient died at 4 weeks 26, and mortality was not reported in another study 24. 
 
The majority of the surviving patients remained seizure free beyond the last follow-up, 
underscoring that these monotherapies are well suited to treat epilepsy in brain tumor 
patients. Also, the marked efficacy of the study medications in preventing seizures with 
consciousness impairment confirms that AED prescribed in this setting are very successful in 
preventing convulsions 3. The target daily dose of LEV was almost reached within two weeks 
and remained relatively low (1125mg). This is lower than in two other Italian studies (mean: 
1710mg 22; range: 1500-4000 24), probably reflecting different treatment policies and patients 
preferences. Conversely, the mean PGB daily dose (294 mg) is almost identical to a recent 
study (279mg) 28, using it however as an add-on. 
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In contrast to other studies, we assessed the AED retention rates at one year using Kaplan-
Meier curves (59% for LEV and 41% for PGB); this analysis is more refined than crude 
percentages, since patients lost to follow-up or dying during the study (and thus “censored” 
for analysis) are still taken into account for the period during which they remained on the 
study medication. Therefore, a comparison with other studies may only be inferred indirectly: 
for LEV, patients still in the study were 100% of 17 patients (follow-up of 1 month) 26; 75% 
of 20 patients at 6 months 27; 89% of 82 patients (follow-up 10-34 months) 24; and 52% of 29 
patients (follow-up one year) 28. While this broad variability, again, may reflect different 
practices and study designs, thresholds to discontinue a given study medication, or add-on a 
further AED, may vary among different study scenarios. Interestingly, retention rates in our 
trial are similar to those reported from the same center for patients with epilepsy without 
tumors at one year: 70% for LEV 29, and 50% for PGB 30. 
 
Although this study was not designed to compare retention rates of LEV and PGB, a 
qualitative analysis of the actuarial seizure control curves shows different patterns among 
these two agents. Patients on LEV tended to reach earlier (at about 50 days) a failure rate of 
25%, while the latter was reached at about 130 days in the PGB group. However, subjects on 
PGB diminished somewhat constantly over time, while those on LEV tended to stabilize on 
the treatment after the first two months. While it is impossible to formally exclude that these 
patterns may reflect a different attitudes of clinicians or participants towards the two agents, 
they might also inform upon the kinetics of the occurrence of side effects, with those 
following LEV appearing earlier. Furthermore, PGB was also discontinued due to impaired 
oral administration following tumor progression, which occurred late (after 9 and 11 months). 
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The global prevalence of side effects in this study appears higher than in the two 
aforementioned studies focused on LEV: a transitory somnolence was reported as the only 
unwanted reaction in 4/82 patients (5%) 24, while among 29 subjects, 3 had restlessness and 2 
somnolence (total: 17%) 22. These differences are likely due to the fact that our study used a 
structured interview and objective clinical data to investigate the side-effect profile in each 
patient, and therefore was probably more sensitive to adverse reactions, as opposed to 
assessments relying on self-reports. Moreover, it is virtually impossible, in this type of 
analysis, to sort out the events that are exclusively due to the AED and not to the underlying 
illness. For example, the high rate of hematological side effects in our data, clearly exceeding 
what is routinely observed in patients with epilepsy due to other causes, may reflect the 
profile of oncological medications, mostly including temozolomide 31. 
 
LEV is well known to induce behavioral and psychiatric side effects in up to 15% of patients 
with epilepsy, in addition to some sedation 32. Accordingly, somnolence, depression, and 
concentration problems were the most frequently found items in our patients. Of note, LEV 
had been demonstrated to have less side effects than phenytoin in patients with brain tumors 
27. PGB tolerability issues are mainly related to somnolence; conversely anxiolytic properties 
may represent a favorable effect 28,33. We mostly observed dizziness, concentration problems, 
and depression. While in our pilot study PGB was discontinued in 2/9 patients because of 
peripheral edema and erectile dysfunction 23; in the add-on study, only 2/25 patients dropped 
out (dizziness, irritability)28. 
 
Our study has some limitations. Its sample size is fairly small, investigators and patients were 
not blinded to treatment, and some underlying heterogeneity of tumor and concomitant 
treatment was unavoidable. However, treatment allocation was random, and there was no 
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obvious or detectable bias of patients or physician towards one of the assigned treatment. The 
real-life situation and pragmatic trial conduct may actually better reflect real-world clinical 
situations than large trials on selected populations. Our patients’ profile was similar to other 
studies, underscoring its potential generalizability. The prospective design, with a structured 
and pre-defined assessment of side effects, represents a further strength. Last but not least, 
this is the largest series to date investigating PGB as monotherapy, and the only prospective 
study specifically addressing seizure control exclusively in tumor patients.  
 
These results confirm that LEV and PGB represent valuable monotherapy options for the 
treatment of patients with epilepsy due to brain tumors, and provide robust data for the design 
of a large phase III trial among different AED in this clinical setting. 
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Table 1: Demographical and clinical characteristics of participating subjects on 
randomization. 
 
Table 2: Study medication and clinical evolution during study follow-up. 
 
Table 3: Study endpoints. 
 
Table 4: New-onset adverse events occurring during follow-up.  
 
 
Figure 1(a,b): Kaplan-Meier curves showing retention of the study medication for LEV (1a) 
and PGB (1b); censored patients are marked. 
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Table 1: Demographical and clinical characteristics of participating subjects on 
randomization. 
 Levetiracetam Pregabalin 
Randomized patients 25 27 
Age (years; mean, ±SD) 54.5 (±12.7) 52.7 (±10.9) 
Female gender  9 (36%) 12 (44%) 
Body mass index (kg/m2) 26.1 (±6.6) 23.6 (±6.0) 
Brain tumor characteristics    
 -High grade (WHO grade III-IV) 17 (68%) 20 (74%) 
 -Recurrent tumor 10 (40%)  6 (22%) 
Seizure types    
-Generalized convulsive 14 (56%) 15 (56%) 
-Focal 11 (44%) 10 (37%) 
-Generalized convulsive and focal  0 (0%)  2 (7%) 
Modified Rankin scale (median, range) 1 (0-3) 1 (0-3) 
Epworth sleepiness scale (median, range) 4 (0-11) 3 (0-13) 
Abnormal neurological examination  18 (72%) 18 (67%) 
Abnormal EEG 20 (83%) 21 (81%) 
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Table 2: Study medication and clinical evolution during study follow-up. 
 levetiracetam pregabalin 
Randomized patients 25 27 
Daily drug dosage   
-At two weeks (mg; mean, ±SD) 1000 (±505) 239 (±82) 
-Maximum (mg; mean, ±SD) 1125 (±511) 294 (±122) 
Poor compliance 2 (8%) 7 (27%) 
Brain tumor progression  9 (38%) 8 (31%) 
Worst modified Rankin scale (median, range) 1 (0-5) 1 (0-5) 
 
 
Table 3: Study endpoints. 
 levetiracetam pregabalin 
Randomized patients 25 27 
Composite endpoint 9 (36%) 12 (44%) 
-status epilepticus 0  0 
-2 seizures with consciousness impairment 1 (4%) 1 (4%) 
-need to interrupt study drug 7 (28%) 7 (26%) 
-need to add-on a second antiepileptic drug 1 (4%) 4 (15%) 
Seizure-free from enrolment until last follow-up 17 (65%) 18 (75%) 
Lost to follow-up 0  3 (11%) 
Death 7 (28%) 5 (19%) 
Survival in the study (days; median, range) 286 (9-431) 166 (0-410) 
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Table 4: New-onset adverse events occurring during follow-up.  
 levetiracetam pregabalin
Leucocytes: grade worsening  14.3% 23.5% 
Hemoglobin: grade worsening  35.7% 21.1% 
Platelets: grade worsening  30.8% 22.2% 
Epworth aggravation ≥ 5 points  44.4% 21.7% 
Anxiety 25.0% 23.1% 
Irritability 12.5% 15.4% 
Depression 37.5% 26.9% 
Psychosis 4.2% 0% 
Concentration problems 37.5% 30.8% 
Infection requiring antibiotics 12.5% 19.2% 
Headache 16.7% 11.5% 
Dizziness 16.7% 30.8% 
Diplopia, blurred vision 8.3% 11.5% 
Rash/Desquamation 0%  7.7% 
Weight increase >10% 4.2%  7.7% 
Limbs Edema  4.2% 15.4% 
Arrhythmia 12.5% 19.2% 
Erectile dysfunction 8.3% 0% 
Libido dysfunction 20.8% 23.1% 
  
